Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019 06; 37(3):461-472.
View in:
PubMed
subject areas
Adaptor Proteins, Signal Transducing
Adaptor Proteins, Signal Transducing
Adult
Adult
Aged
Aged
Antibodies, Bispecific
Antibodies, Bispecific
Antibodies, Monoclonal
Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Agents
Calcium-Binding Proteins
Calcium-Binding Proteins
Female
Female
Follow-Up Studies
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Gene Expression Regulation, Neoplastic
Humans
Humans
Male
Male
Maximum Tolerated Dose
Maximum Tolerated Dose
Middle Aged
Middle Aged
Neoplasms
Neoplasms
Prognosis
Prognosis
Tissue Distribution
Tissue Distribution
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A
authors with profiles
Raid Aljumaily